trending Market Intelligence /marketintelligence/en/news-insights/trending/ianrdnwx0a8s-ndvcc7_fq2 content esgSubNav
In This List

Clovis Oncology appoints 2 new directors

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Clovis Oncology appoints 2 new directors

Clovis Oncology Inc. said it appointed Robert Azelby and Richard Fair to the company's board of directors.

Azelby has been serving as the president, CEO and director of Alder Biopharmaceuticals Inc. since June.

Fair has worked as president, CEO and a board member of Bellicum Pharmaceuticals Inc. since January 2017.

Boulder, Colo.-based Clovis Oncology is a biopharmaceutical company focused on developing anti-cancer agents.